“4,000% or 5,000% Over Five or Six Years”: Why Patient Investors in NVDA, AMD, and LLY Are Winning

Photo of Don Lair
By Don Lair Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
“4,000% or 5,000% Over Five or Six Years”: Why Patient Investors in NVDA, AMD, and LLY Are Winning

© dobok / Getty Images

On a recent episode of Earn Your Leisure titled “The #1 Investing Mistake Keeping You Broke,” co-host E delivered a blunt diagnosis for retail investors: stop trading the stocks you should be holding. “The ones that are leading now will lead,” he said, warning that top companies could compound 4,000% or 5,000% over five or six years while impatient traders walk away with 200% profits that get “blown on a car or a vacation or somebody who doesn’t love you.”

His example: an investor who put $100,000 into NVIDIA in 2023 and doubled their money, then exited. The numbers since suggest that decision was costly.

NVIDIA: The Trade That Kept Paying

NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) has returned 1,454.69% since January 3, 2023, and 1,484.53% over five years. The fundamentals back the run. Q4 FY2026 revenue hit $68.13 billion, up 73.2% year over year, with EPS of $1.62 versus a $1.52 estimate. Full-year FY2026 revenue reached $215.94 billion with $96.58 billion in free cash flow. CEO Jensen Huang told investors “the agentic AI inflection point has arrived” in the Q4 release.

NVDA earnings explorer

AMD: The Other AI Compounder

Advanced Micro Devices (NASDAQ:AMD) is up 259.3% over the past year and 96.58% year to date. Q1 2026 revenue came in at $10.25 billion, up 37.9% YoY, with Data Center growing 57% to $5.78 billion. CEO Lisa Su flagged that “Customer engagement around MI450 Series and Helios is strengthening, with leading customer forecasts exceeding our initial expectations.” The Meta deal alone covers up to 6 gigawatts of Instinct GPUs.

Eli Lilly: The GLP-1 Volume Story

Eli Lilly (NYSE:LLY) has returned 427% over five years. Q1 2026 revenue jumped 55.5% to $19.80 billion, with Mounjaro at $8.66 billion (up 125%) and Zepbound at $4.16 billion (up 80%). EPS of $8.55 crushed the $6.79 consensus. Management raised full-year guidance to $82.0 to $85.0 billion in revenue. Analysts carry an average target of $1,210 on the stock.

The Real Cost of Early Exits

Sean Duffy hammered the same point with a fresh example: a company that IPO’d in February 2025 at $1.95 has jumped to $12.89, a 3,400% gain that listeners watched develop “week after week” without acting. E framed the behavioral trap directly: it is “crazy as hell” to “trade an asset to then spend it on a liability.” Reddit threads suggest the pain is real. One viral r/wallstreetbets post celebrated “AMD +21k % – 10 Years of Diamond Hands”, while another anxious holder posted “I got into AMD at ~$60 per share and now have zero strategy for it.” Patience, in each of these three names, has done the heavy lifting.

Contact [email protected] for any questions or corrections.

Photo of Don Lair
About the Author Don Lair →

Don Lair writes about options income, dividend strategy, and the kind of boring-but-durable investing that actually funds retirement. He's the founder of FITools.com, an independent contributor to 24/7 Wall St., and a former writer for The Motley Fool.

Continue Reading

Top Gaining Stocks

KKR
KKR Vol: 8,319,583
AXON Vol: 1,494,220
APO Vol: 5,785,745
JBL Vol: 1,443,292
MPC Vol: 3,183,068

Top Losing Stocks

CTRA Vol: 73,319,495
VTR Vol: 4,890,102
DDOG Vol: 4,419,836
HON Vol: 5,436,294
WELL Vol: 3,315,064